Navigation Links
Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer
Date:5/4/2015

New York, New York (PRWEB) May 04, 2015

Takeda Pharmaceuticals Corp. has agreed to pay as much as $2.4 billion to settle thousands of Actos lawsuits (http://www.theactoslawsuitcenter.com/) that allege the Type 2 diabetes medication increases the risk that a patient will develop bladder cancer. According to court documents issued on April 28th, if 95% of those eligible for the Actos settlement accept its terms, the accord will resolve nearly 9,000 bladder cancer cases currently pending in courts around the country, including thousands that have been filed in the multidistrict litigation underway in U.S. District Court, Western District of Louisiana. (In re: Actos Product Liability Litigation, MDL No. 2299)

“Our Firm is representing a number of clients who have filed Actos lawsuits in the federal litigation. We are pleased that Takeda has moved to resolve this litigation, as the newly-announced Actos settlement could allow thousands of plaintiffs to avoid protracted and expensive court proceedings,” says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm continues to offer free legal evaluations to individuals who were treated with Actos for a year or more, and who allegedly went on to develop bladder cancer due to their use of the drug.

Actos Settlement Terms

According to court records filed in the Western District of Louisiana on April 28th, Takeda will pay $2.37 billion if 95% of eligible plaintiffs agree to participate in the Actos settlement program. However, the total payout will rise to $2.4 billion if at least 97% percent elect to particpate. Eligible plaintiffs include Type 2 diabetes patients who were prescribed an Actos medication, including Actos, ACTOplus Met, ACTOplus Met XR, or Duetact, prior to December 1, 2011, and who were diagnosed with bladder cancer prior to April 28, 2015. According to Bloomberg News, the settlement could provide each eligible plaintiff with a payment of more than $296,000. However, certain factors, including age, smoking history and exposure to toxins, could result in a reduced award.*

According to court filings, all of the Actos lawsuits pending in the Western District of Louisiana and elsewhere allege that Takeda Pharmaceuticals concealed data linking the use of Actos to the development of bladder cancer. The Actos litigation has been growing since 2011, when the U.S. Food & Drug Administration warned that long-term use of the medication was associated with a doubling of the risk of bladder cancer.

Bernstein Liebhard LLP has updated its website with the most current information regarding the proposed Actos settlement. To learn more about filing an Actos lawsuit, and to arrange for a free, no-obligation review of your case, please visit the site or call 800-511-5092.

*bloomberg.com/news/articles/2015-04-28/takeda-said-to-agree-to-pay-2-3-billion-to-settle-actos-cases, Bloomberg News, April 28, 2015

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The National Law Journal has recognized Bernstein Liebhard for twelve consecutive years as one of the top plaintiffs' firms in the country. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
info (at) consumerinjurylawyers (dot) com
http://www.theactoslawsuitcenter.com/
https://plus.google.com/115936073311125306742?rel=author

Read the full story at http://www.prweb.com/releases/actos-lawsuit-settlement/actos-bladder-cancer/prweb12699408.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related medicine news :

1. $2.4 Billion Settlement Reached in Actos Products Liability Litigation
2. Are the Lactose Intolerant Safer From Some Cancers?
3. Actos Lawsuits Continue To Be Filed By Wright & Schulte LLC Contending Development of Bladder Cancer After Taking Type Two Diabetes Medication
4. Wright & Schulte LLC Files Another Actos Lawsuit Alleging The Diabetes Medication Caused A Maryland Resident To Develop Bladder Cancer
5. Takeda and Eli Lilly Ordered to Pay a Combined $9 Billion in Punitive Damages over Bladder Cancer Allegations in Actos Litigation Parker Waichman LLP Comments
6. Actos Lawsuit News: Federal Judge Won’t Dismiss $9 Billion Verdict in First Federal Actos Bladder Cancer Trial, Bernstein Liebhard LLP Reports
7. The Law Office of Melinda J. Helbock A.P.C. Comments on Decision to Uphold $9 Billion Actos Award
8. Actos Lawsuit Filed by Wright & Schulte LLC Contends NY Man Developed Bladder Cancer after Taking the Type II Diabetes Medication
9. Claim that raw milk reduces lactose intolerance doesnt pass smell test, study finds
10. Universal Treatment and Recovery Center Treats Lactose Intolerance
11. Actos Lawsuit News: Nation’s Third Actos Trial Involving Bladder Cancer Allegations Now Underway in Nevada State Court, Bernstein Liebhard LLP Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... NY (PRWEB) , ... October 13, 2017 , ... Ellevate ... people in business to advocate for action towards gender equality at their inaugural Summit ... from around the globe, and reached a social audience of over 3 million. To ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) ... FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... Morris F. Collen, a pioneer in the field of medical informatics, this prestigious award ...
(Date:10/12/2017)... Malvern, PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best ... New York City on October 11, 2017. , The annual award competition recognizes editorial ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
(Date:10/10/2017)... Oct. 10, 2017  NDS received FDA 510(k) clearance in May ... battery-powered display stand specifically designed for endoscopy environments. An innovative secondary ... a clinical solution to support the improvement of patient outcomes, procedural ... ... ...
(Date:10/5/2017)... , Oct. 5, 2017  In response ... of Oral and Maxillofacial Surgeons (AAOMS) released prescribing ... – to be used as a first-line therapy ... Recognizing the ... AAOMS White Paper "Opioid Prescribing: Acute and Postoperative ...
Breaking Medicine Technology: